In a rare moment of bicameral success, 49 U.S. House of Representatives and Senate members introduced legislation to make permanent the Medicare telehealth coverage that had been introduced as a temporary measure during the COVID-19 coronavirus pandemic.
On February 5, 2021, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi®) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified—including DLBCL arising from indolent lymphoma—high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Social connection with others is widely considered a fundamental human need, crucial to well-being and survival. A growing body of literature is evaluating cancer caregivers’ needs, yet strategies to address loneliness, which has broadly detrimental effects on caregivers, are still in their infancy. Therefore, my goal is to identify better support strategies for caregivers as they support their loved ones with cancer.
Watching patients—or even colleagues—suffer or die, not being able to protect yourself with the right personal protective equipment, worry about exposing loved ones, and the challenge of balancing it all contribute to an immeasurable psychological burden for nurses and other healthcare professionals during a pandemic. Studies show that the effects are serious, leading to post-traumatic stress, anxiety, depression, and, in some cases, suicide among providers.
Drug pricing is a bipartisan issue that ranks very high on public opinion polling, and patients with cancer in particular feel the effects of an unregulated market.
On February 5, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to umbralisib (Ukoniq™), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and adult patients with relapsed or refractory follicular lymphoma who have received at least three prior lines of systemic therapy.
In its year-end wrap-up meeting on December 8, 2020, the ONS Board of Directors focused on oncology nursing leadership development, both within the general nursing profession as well as within the Society itself. It also finalized the topics for the annual ONS membership survey for January 2021. Highlights from those conversations follow, and ONS members can read a full report in the meeting minutes.
During his final State of the Union address in January 2016, former President Barack Obama appointed Joe Biden the lead on a new initiative: the National Cancer Moonshot. The goal was to find treatments, cures, and more understanding about cancer—a decade’s worth of progress in just five years.
One of President Joe Biden’s first executive orders was rejoining the World Health Organization (WHO). He also signed executive orders to require masks on all federal grounds and asked agencies to extend moratoriums on evictions and federal student loan payments, but the WHO executive order has particular implications for cancer care.
As treatments have advanced and patients and providers have more options, cure and survivorship rates for lymphomas are improving: five-year survival rates for Hodgkin and non-Hodgkin lymphoma are 86% and 71%, respectively. Despite good results from treatment, research indicates that lymphoma survivors carry a significant amount of late and chronic effects. Even in a complete remission, late effects of treatment present a burden for patients' physical and psychosocial well-being.